Stockscreener 앱 받기
121.72
4.01%
-5.09
시간 외 거래:
119.04
-2.68
-2.20%
전일 마감가:
$126.81
열려 있는:
$127.49
하루 거래량:
473.82K
Relative Volume:
0.68
시가총액:
$3.50B
수익:
$267.23M
순이익/손실:
$-83.50M
주가수익비율:
-39.14
EPS:
-3.11
순현금흐름:
$-59.99M
1주 성능:
+2.93%
1개월 성능:
-1.20%
6개월 성능:
+31.42%
1년 성능:
+121.31%
1일 변동 폭
$119.79
$129.35
1주일 범위
$118.00
$132.00
52주 변동 폭
$54.14
$136.00
Genedx Holdings Corp Stock (WGS) Company Profile
명칭
Genedx Holdings Corp
전화
888-729-1206
주소
333 LUDLOW STREET, STAMFORD
WGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
121.72 | 3.64B | 267.23M | -83.50M | -59.99M | -3.11 |
|
TMO
Thermo Fisher Scientific Inc
|
524.80 | 201.90B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
202.46 | 146.42B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
616.15 | 50.30B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
136.62 | 39.72B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
198.17 | 34.51B | 15.70B | 1.24B | 2.01B | 6.9036 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2025-05-15 | 개시 | Guggenheim | Buy |
| 2025-05-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-07-10 | 개시 | Craig Hallum | Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
모두보기
Genedx Holdings Corp 주식(WGS)의 최신 뉴스
Analyzing GeneDx Holdings Corp. with risk reward ratio chartsJuly 2025 Movers & Safe Capital Growth Trade Ideas - newser.com
Is it time to cut losses on GeneDx Holdings Corp.2025 Performance Recap & Consistent Income Trade Ideas - newser.com
Technical signs of recovery in GeneDx Holdings Corp. Equity Warrant2025 Price Momentum & Weekly Setup with ROI Potential - newser.com
Can volume confirm reversal in GeneDx Holdings Corp. Equity Warrant2025 Earnings Impact & Risk Controlled Daily Trade Plans - newser.com
Using Python tools to backtest GeneDx Holdings Corp. strategiesQuarterly Investment Review & Real-Time Market Sentiment Alerts - newser.com
Is GeneDx Holdings Corp. stock a safe haven assetPortfolio Value Report & Risk Controlled Daily Trade Plans - newser.com
Technical analysis overview for GeneDx Holdings Corp. stock2025 Big Picture & Accurate Entry and Exit Point Alerts - newser.com
Using RSI to spot recovery in GeneDx Holdings Corp.Market Risk Summary & Capital Protection Trade Alerts - newser.com
Top chart patterns to watch in GeneDx Holdings Corp.2025 Institutional Moves & Growth Focused Entry Point Reports - newser.com
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics Annual Meeting - MarketScreener
Genedx to launch autism partnership program to expand access to exome and genome testing - MarketScreener
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program - Stock Titan
What data driven models say about GeneDx Holdings Corp. Equity Warrant’s futureJuly 2025 Decliners & Community Consensus Picks - newser.com
Will GeneDx Holdings Corp. rebound enough to break evenDip Buying & Reliable Entry Point Alerts - newser.com
How to escape a deep drawdown in GeneDx Holdings Corp.Rate Hike & High Yield Equity Trading Tips - newser.com
GeneDx's (WGS) Sell (D) Rating Reaffirmed at Weiss Ratings - MarketBeat
GeneDx Holdings Corp. Experiences Evaluation Revision Amid Strong Market Performance and Dynamics - Markets Mojo
Nearly 1M exomes: GeneDx presents 14 ASHG studies on gNBS, autism, ML and long-read validation - Stock Titan
GeneDx Holdings Corp. $WGS Stake Trimmed by Gagnon Securities LLC - MarketBeat
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025 - Business Wire
Slow Capital Inc. Makes New Investment in GeneDx Holdings Corp. $WGS - MarketBeat
How to integrate GeneDx Holdings Corp. Equity Warrant into portfolio analysis tools2025 Price Momentum & Expert Approved Trade Ideas - newser.com
Is GeneDx Holdings Corp. stock ready for breakoutIPO Watch & Reliable Intraday Trade Plans - newser.com
Tools to monitor GeneDx Holdings Corp. recovery probability2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
Assessing GeneDx (WGS) Valuation Following BEACONS Launch and NIH-Backed Expansion in Newborn Genomics - simplywall.st
Evaluating GeneDx Holdings Corp. Equity Warrant with trendline analysisMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
Is GeneDx Holdings Corp. Equity Warrant stock positioned for long term growthOptions Play & Reliable Entry Point Trade Alerts - newser.com
What machine learning models say about GeneDx Holdings Corp. Equity WarrantQuarterly Performance Summary & Accurate Technical Buy Alerts - newser.com
Detecting price anomalies in GeneDx Holdings Corp. with AIWeekly Risk Report & Verified Entry Point Signals - newser.com
How to read the order book for GeneDx Holdings Corp.M&A Rumor & Risk Managed Investment Entry Signals - newser.com
What MACD signals say about GeneDx Holdings Corp. Equity WarrantPortfolio Return Summary & Daily Profit Focused Screening - newser.com
GeneDx (NASDAQ:WGS) Stock Rating Lowered by Zacks Research - MarketBeat
How Investors May Respond To GeneDx Holdings (WGS) Launching Nationwide Genomic Newborn Screening With NIH Support - simplywall.st
How the BEACONS Genomic Newborn Screening Initiative Could Shape GeneDx Holdings (WGS) Pediatric Genomics Leadership - simplywall.st
What’s next for GeneDx Holdings Corp. Equity Warrant stock priceJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Best data tools to analyze GeneDx Holdings Corp. Equity Warrant stockWeekly Earnings Recap & AI Powered Buy/Sell Recommendations - newser.com
GeneDx Holdings Corp. Equity Warrant recovery potential after sell offNew Guidance & Real-Time Market Trend Scan - newser.com
Will GeneDx Holdings Corp. Equity Warrant benefit from macro trendsJuly 2025 Trade Ideas & Entry Point Confirmation Signals - newser.com
Genedx Holdings Corp (WGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Genedx Holdings Corp 주식 (WGS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 30 '25 |
Option Exercise |
32.67 |
1,246 |
40,707 |
10,001 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 30 '25 |
Sale |
108.38 |
6,609 |
716,261 |
3,392 |
0.17%
2.19%
자본화:
|
볼륨(24시간):